NEW YORK, NY / ACCESSWIRE / September 6, 2019 / Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Aclaris Therapeutics, Inc. (ACRS) from May 8, 2018 through June 20, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aclaris investors under the federal securities laws.
If you wish to serve as lead plaintiff, you must move the Court no later than September 30, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to obtain a recovery is not dependent upon being a lead plaintiff. If you wish to join the http://zhanginvestorlaw.com/join-action-form/?slug=aclaris-therapeutics-inc&id=1965 or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. or Spencer Lee toll-free at 800-991-3756 or email firstname.lastname@example.org, email@example.com for information on the class action.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Aclaris’s advertising materials minimized the risks and overstated the efficacy of ESKATA to generate sales; (2) Aclaris was reasonably likely to face regulatory scrutiny; and (3) as a result of the foregoing, defendants’ positive statements about Aclaris’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class has not been certified. You may retain counsel of your choice. You may take no action at this time and be an absent class member. Your ability to obtain a recovery is not dependent upon being a lead plaintiff.
Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.
Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
tel: (800) 991-3756
SOURCE: Zhang Investor Law P.C.
View source version on accesswire.com: